[go: up one dir, main page]

BRPI0509881A - therapeutic combination for treatment of alzheimer's disease - Google Patents

therapeutic combination for treatment of alzheimer's disease

Info

Publication number
BRPI0509881A
BRPI0509881A BRPI0509881-5A BRPI0509881A BRPI0509881A BR PI0509881 A BRPI0509881 A BR PI0509881A BR PI0509881 A BRPI0509881 A BR PI0509881A BR PI0509881 A BRPI0509881 A BR PI0509881A
Authority
BR
Brazil
Prior art keywords
disease
alzheimer
treatment
therapeutic combination
treating alzheimer
Prior art date
Application number
BRPI0509881-5A
Other languages
Portuguese (pt)
Inventor
Gregg H Larson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0509881A publication Critical patent/BRPI0509881A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

COMBINAçãO TERAPêUTICA PARA TRATAMENTO DA DOENçA DE ALZHEIMER. A presente invenção refere-se a composições farmacêuticas úteis para tratar a Doença de Alzheimer. Também são descritos métodos para tratar a Doença de Alzheimer.THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMER'S DISEASE. The present invention relates to pharmaceutical compositions useful for treating Alzheimer's disease. Also described are methods for treating Alzheimer's disease.

BRPI0509881-5A 2004-04-14 2005-04-04 therapeutic combination for treatment of alzheimer's disease BRPI0509881A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
PCT/IB2005/000923 WO2005099823A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Publications (1)

Publication Number Publication Date
BRPI0509881A true BRPI0509881A (en) 2007-10-16

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509881-5A BRPI0509881A (en) 2004-04-14 2005-04-04 therapeutic combination for treatment of alzheimer's disease

Country Status (14)

Country Link
EP (1) EP1737539A1 (en)
JP (1) JP2007532624A (en)
KR (1) KR20060133008A (en)
CN (1) CN1960781A (en)
AU (1) AU2005232447A1 (en)
BR (1) BRPI0509881A (en)
CA (1) CA2562069A1 (en)
IL (1) IL178120A0 (en)
MX (1) MXPA06011969A (en)
NO (1) NO20065196L (en)
RU (1) RU2006136361A (en)
TW (1) TW200533341A (en)
WO (1) WO2005099823A1 (en)
ZA (1) ZA200608239B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (en) * 2007-10-03 2014-04-01 Kowa Co Nerve cell death inhibiting agent
EP3903767A1 (en) * 2016-02-11 2021-11-03 SigmaThera SAS Igmesine for use in the treatment of neurodegenerative diseases
HRP20241019T1 (en) * 2019-06-14 2024-11-08 Joshua O. Atiba Triple pharmaceutical composition for proteinaceous infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
WO2003082298A1 (en) * 2002-04-02 2003-10-09 Janssen Pharmaceutica N.V. Statin therapy for enhancing cognitive maintenance
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
AU2003291910B2 (en) * 2002-12-24 2009-10-01 Bellus Health (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
EA009668B1 (en) * 2003-03-19 2008-02-28 Арес Трейдинг С.А. Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
IL178120A0 (en) 2006-12-31
ZA200608239B (en) 2008-06-25
RU2006136361A (en) 2008-04-20
MXPA06011969A (en) 2006-12-15
AU2005232447A1 (en) 2005-10-27
KR20060133008A (en) 2006-12-22
WO2005099823A1 (en) 2005-10-27
NO20065196L (en) 2007-01-03
CA2562069A1 (en) 2005-10-27
CN1960781A (en) 2007-05-09
EP1737539A1 (en) 2007-01-03
JP2007532624A (en) 2007-11-15
TW200533341A (en) 2005-10-16

Similar Documents

Publication Publication Date Title
EA200901373A1 (en) AMINOGETEROCYCLIC COMPOUNDS
BRPI0413245A (en) 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
BR0315158A (en) Pyrazole Compounds for the Treatment of Neurodegenative Disorders
BR0316350A (en) Diaminotriazoles useful as protein kinase inhibitors
UY28011A1 (en) TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
DOP2005000040A (en) IMIDAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
ATE475650T1 (en) POSITIVE ALLOSTERIC QUINOLONE M1 RECEPTOR MODULATORS
ATE530544T1 (en) BENZYL-SUBSTITUTED POSITIVE ALLOSTERIC QUINOLONE M1 RECEPTOR MODULATORS
BRPI0407662B8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
UY30377A1 (en) FUSIONATED TRICYCLE INHIBITORS OF SULFONAMIDE OF GAMA-SECRETASA
BR0307998A (en) Substituted hydroxyethylamines
EA200600971A1 (en) APPLICATION OF SUBSTITUTED 2 - AMINOTHETRALINES FOR THE PREVENTION TREATMENT OF PARKINSON'S Disease
BRPI0413709A (en) compounds for the treatment of neurodegenerative disorders
ATE371724T1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
UA101393C2 (en) COMPOSITIONS AND USE OF TRIAZOLE DERIVATIVES FOR TREATING β-AMYLOID DISEASES AND SYNUCLEINOPATHIES
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE409480T1 (en) PYRAZOLOA3,4-BUPYRIDINE-6-ONE AS GSK-3 INHIBITORS
EA200801481A1 (en) 5- (AROSULFONYL) PYRAZOLOPIPERIDES
CY1110401T1 (en) PRODUCTION OF 1-PHENYLCOCARCAROXYLIC ACIDS FOR TREATMENT OF NEUROCOLOGICAL DISEASES
PT1778837E (en) Treatment of neurodegenerative diseases by the use of scd4 inhibitors
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
BRPI0509477A (en) sulfonamide compounds for the treatment of neurodegenerative disorders
EA200501865A1 (en) ANALOGUES OF TIOVOLFRAMATOV AND THEIR APPLICATION
BRPI0509881A (en) therapeutic combination for treatment of alzheimer's disease
BRPI0514303A (en) pharmaceutical composition and method for treating neurodegenerative disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/445 (2006.01), A61P 25/28 (2006.01), A61K